Major Advances in Psychiatry: 2015 - 2026

1. Ketamine and Esketamine - A Paradigm Shift in Depression Treatment

• Esketamine (Spravato) nasal spray received FDA approval in March 2019 for treatment-resistant depression (TRD) and in August 2020 for major depressive disorder (MDD) with acute suicidal ideation - the first ever FDA approval specifically targeting suicidal ideation.
• Meta-analyses confirm robust efficacy in TRD: pooled response rates significantly exceed those of conventional augmentation strategies (PMID: 35688035).
• A 2022 Lancet Psychiatry systematic review assessed maintenance ketamine therapy, finding it sustains response in a subset of patients (PMID: 36244360).
• A 2025 meta-analysis in American Journal of Psychiatry (PMID: 39876682) confirmed esketamine's efficacy and delineated its safety profile.

2. Psychedelic-Assisted Therapy - A Scientific Renaissance

Psilocybin

• A landmark 2022 Phase II RCT in NEJM (PMID: 36322843) by Goodwin et al. showed that a single high dose (25 mg) of psilocybin produced significant reductions in depression scores vs. 1 mg (active placebo) in treatment-resistant MDD.
• A Nature Medicine RCT (2022, PMID: 35411074) showed psilocybin therapy increases global brain integration - neuroplastic changes correlated with therapeutic outcome.
• 12-month follow-up data confirm durable antidepressant effects (PMID: 35166158).
• A 2024 Cochrane meta-analysis (PMID: 39260823) found psychedelic-assisted therapy reduces anxiety, depression, and existential distress in life-threatening illness.

MDMA for PTSD

• Phase III trials by MAPS showed MDMA-assisted therapy produced response rates of 67-71% and remission rates of 47-67% in PTSD - far exceeding current first-line treatments.
• A 2024 systematic review/meta-analysis (PMID: 39381877) confirmed significant PTSD symptom reduction in RCTs.
• The FDA issued a Complete Response Letter in August 2024 (not an outright rejection) requesting an additional Phase III trial, reflecting debate around trial design rather than disbelief in efficacy. The field continues active research into this.

3. Neuroactive Steroids - Entirely New Drug Class

• Brexanolone (Zulresso): FDA approved in March 2019 - the first drug ever approved specifically for postpartum depression (PPD). It is an IV formulation of allopregnanolone, a progesterone metabolite, acting as a positive allosteric modulator of both synaptic and extrasynaptic GABA-A receptors.
• Zuranolone (Zurzuvae): FDA approved in August 2023 - the first oral neuroactive steroid for PPD and MDD. It is a 14-day course, making it far more practical than brexanolone's 60-hour IV infusion.
• These represent a completely novel mechanism (GABA modulation, not monoamine reuptake) and validate neuroactive steroids as a major antidepressant class.

4. Transcranial Magnetic Stimulation (TMS) - Expanded Indications and Protocols

• 2018: FDA cleared TMS for OCD (the first non-drug, non-ECT treatment for OCD approved by FDA).
• 2020: FDA cleared TMS for smoking cessation.
• 2024: FDA clearance of TMS for adolescents with MDD (NeuroStar), marking a major expansion into younger populations.
• September 2025: BrainsWay received FDA clearance for an accelerated deep TMS protocol that compresses the initial treatment phase from 4 weeks to just 6 days.
• November 2025: BrainsWay received FDA clearance for deep TMS in adolescents ages 15-21.
• Theta burst stimulation (TBS): A newer protocol delivering full TMS courses in 3 minutes (vs. 37 minutes traditionally), now widely used and evidence-supported (PMID: 40302403).
• Precision TMS: Connectivity-guided TMS using fMRI to target the subgenual cingulate cortex network - trials showing significantly higher remission rates than conventional targeting (PMID: 37979642).

5. Deep Brain Stimulation (DBS) for Psychiatric Disorders

• DBS, long established for Parkinson's disease, is now being actively trialed for treatment-resistant depression, OCD, and anorexia nervosa.
• For OCD: DBS of the anterior limb of the internal capsule/nucleus accumbens has shown significant symptom reduction; it carries a humanitarian device exemption in the US.
• Adaptive (closed-loop) DBS: Systems like Medtronic's BrainSense record local field potentials from the implanted electrodes and automatically adjust stimulation based on real-time brain activity - a major evolution over traditional open-loop systems.
• DBS for depression remains investigational but has shown durable responses in some of the most severely ill, treatment-refractory patients.

6. Precision Psychiatry and Pharmacogenomics

• Pharmacogenomic testing (e.g., CYP2D6, CYP2C19 genotyping) now guides antidepressant and antipsychotic selection, reducing trial-and-error prescribing. Products like GeneSight are commercially available.
• A 2022 Trends in Pharmacological Sciences review (PMID: 36307251) outlined how gene variants substantially alter metabolism of SSRIs, SNRIs, TCAs, and antipsychotics.
• Bipolar disorder genomics: A landmark 2025 Nature meta-analysis (PMID: 39843750) identified novel biological mechanisms and subtypes in bipolar disorder through large-scale GWAS, pointing toward biologically-informed diagnosis.
• Polygenic risk scores for schizophrenia, depression, and bipolar disorder are moving toward clinical utility in risk stratification.

7. Neuroinflammation and Immunopsychiatry - A New Etiological Framework

• Growing evidence implicates immune dysregulation in depression, bipolar disorder, and schizophrenia.
• A 2026 Mount Sinai study demonstrated that major depressive disorder shares immune cell abnormalities with inflammatory skin diseases, suggesting that dupilumab (an IL-4/IL-13 blocker approved for eczema) may be repurposable for depression. A clinical trial has been funded.
• Inflammatory biomarkers (CRP, IL-6, TNF-alpha) now inform patient stratification - patients with elevated inflammation respond poorly to SSRIs but may benefit from anti-inflammatory add-ons.
• Microglia have been identified as central mediators of neuroinflammatory depression. PET imaging using TSPO ligands can now quantify microglial activation in living patients.

8. Digital Psychiatry and AI

• Digital phenotyping: Passive data collected from smartphones (GPS, keystroke dynamics, speech patterns, social media activity) can detect early relapse in bipolar disorder and schizophrenia. A 2025 systematic review (PMID: 40408762) validated digital phenotyping in distinguishing unipolar from bipolar depression.
• AI chatbots and conversational agents: Tools like Woebot, Wysa, and Limbic have demonstrated efficacy in delivering cognitive behavioral therapy (CBT) at scale; a 2022 Psychiatric Quarterly review (PMID: 35212940) summarized their clinical potential.
• Natural language processing (NLP): Used to analyze speech transcripts and clinical notes to predict suicide risk, psychosis onset, and treatment response - several hospital systems have deployed these tools clinically.
• Machine learning models for treatment selection: Predicting which patients will respond to antidepressants vs. psychotherapy based on baseline EEG, MRI, and clinical features.
• A 2025 Frontiers in Psychiatry review (PMID: 40687277) outlined the framework for digital psychiatry as a clinical discipline.

9. New Pharmacological Agents for Specific Conditions

10. PTSD Treatment Advances

• A comprehensive 2024 state-of-the-art review in Current Neuropharmacology (PMID: 37132142) summarized advances including stellate ganglion block, intranasal oxytocin, and trauma-focused psychotherapies.
• Prolonged Exposure (PE) and EMDR have been further validated by large RCTs and meta-analyses as first-line psychotherapies.
• Prazosin for PTSD nightmares has been better characterized (though recent large trials have shown mixed results, highlighting heterogeneity of PTSD).

11. Understanding Schizophrenia Biology

• The largest-ever GWAS for schizophrenia (2022, Trubetskoy et al., Nature) identified 287 common variant associations, implicating glutamatergic and dopaminergic synaptic pathways at unprecedented resolution.
• Complement cascade proteins (especially C4) have been linked to synaptic pruning in adolescence - a mechanism potentially explaining early-onset psychosis.
• This is enabling drug target identification for truly novel antipsychotic mechanisms beyond D2 blockade, after 70 years of largely the same approach.

Summary Table

Additional Major Advances in Psychiatry (Not Previously Covered)

12. GLP-1 Receptor Agonists - An Unexpected Psychiatric Frontier

• A landmark 2025 JAMA Psychiatry systematic review and meta-analysis (PMID: 40366681) found GLP-1 agonists significantly reduce depressive symptoms, suicidal ideation risk, and anxiety across RCTs.
• A 2024 meta-analysis in Diabetes, Obesity & Metabolism (PMID: 38449004) confirmed mood and anxiety benefits in RCTs.
• Mechanism hypotheses: GLP-1 receptors are present in the hypothalamus, limbic system, and VTA (reward circuit). They reduce neuroinflammation, modulate dopamine, and may directly influence addictive behavior and impulsivity.
• Observational data suggests GLP-1 agonists reduce alcohol consumption, nicotine use, and opioid use - potentially a new approach for addiction psychiatry.
• A 2025 Nervenarzt review explicitly asks whether GLP-1 agonists should be considered a pharmacological treatment option for psychiatric illness (PMID: 40042613).
• Additionally, since weight gain from antipsychotics (olanzapine, clozapine) is one of the most common reasons for non-adherence, GLP-1 agonists are now being co-prescribed in psychotic disorder patients - a 2024 review (PMID: 39225182) specifically addressed their role in managing antipsychotic-induced weight gain.

13. Orexin Receptor Antagonists - A New Class for Insomnia

• Suvorexant (Belsomra): FDA approved 2014, the first in class. A review published in 2022 in Current Psychiatry Reports (PMID: 35972717) consolidated evidence.
• Lemborexant (Dayvigo): FDA approved 2019, with superior sleep onset efficacy compared to suvorexant.
• Daridorexant (Quviviq): FDA approved 2022 - the most clinically refined, with evidence of improving both sleep and daytime functioning (a first for insomnia drugs).
• A 2025 network meta-analysis (PMID: 40555730) compared all three head-to-head: lemborexant and daridorexant showed the best balance of efficacy and tolerability.
• A 2024 review explored their role in Alzheimer's disease sleep disorders (PMID: 39365407) - highly relevant since sleep disturbance accelerates cognitive decline.
• These agents have displaced benzodiazepines and z-drugs as the preferred pharmacological option for chronic insomnia in multiple guidelines.

14. ADHD - New Non-Stimulant Agents and Expanded Recognition

• Viloxazine ER (Qelbree): FDA approved 2021 for children/adolescents, 2023 for adults - a selective norepinephrine reuptake inhibitor (SNRI) with additional serotonergic activity. First new non-stimulant ADHD drug since atomoxetine (2003). A 2024 Expert Review of Neurotherapeutics review (PMID: 38771653) highlighted the expanding non-stimulant landscape.
• Arynta (lisdexamfetamine oral solution): FDA approved June 2025 - the first oral liquid formulation of lisdexamfetamine, addressing needs of patients who cannot swallow capsules.
• Adult ADHD recognition: Major clinical guidelines were updated to formally acknowledge that ADHD is a lifelong condition. Recognition and treatment rates in adults have significantly increased over this decade.
• A 2025 BMJ umbrella review (PMID: 41297970) comprehensively evaluated benefits and harms of all ADHD interventions to support shared decision-making.
• A 2025 Lancet Psychiatry network meta-analysis (PMID: 40203844) provided the most rigorous comparative cardiovascular safety data on stimulants across all age groups.

15. Alzheimer's Disease - Blood Biomarkers and Disease-Modifying Drugs

• Lecanemab (Leqembi): FDA full approval in 2023 - the first anti-amyloid monoclonal antibody with demonstrated slowing of clinical decline in early Alzheimer's (18% slower decline in CDR-SB score vs. placebo in Phase III).
• Donanemab (Kisunla): FDA approved July 2024, showing 35% slowing of decline in patients with low-medium tau burden. A 2025 update refined the titration schedule.
• First blood-based diagnostic test: In May 2025, Lumipulse Plasma (Fujirebio) received FDA clearance as the first blood test for Alzheimer's biomarkers (p-tau 217/Aβ42 ratio) - replacing or supplementing lumbar puncture or PET scans for confirmation of amyloid pathology. This is a watershed moment for accessible diagnosis.
• These drugs validate the amyloid cascade hypothesis after decades of failed trials, though debate continues about the magnitude of clinical benefit vs. ARIA (amyloid-related imaging abnormalities) risk.

16. Schizophrenia - Clozapine REMS Elimination and New Agents

• Clozapine REMS eliminated (February 2025): The FDA eliminated the complex Risk Evaluation and Mitigation Strategy for clozapine, which had required registration in a national database and ANC testing before every dispense. The new requirement is simply a standard ANC monitoring protocol. This is a major access improvement - clozapine remains the only evidence-based treatment for treatment-resistant schizophrenia but was historically under-prescribed because of administrative burden.
• Brilaroxazine: A third-generation antipsychotic in late-stage trials (fast track FDA designation 2025) with a dopamine-serotonin modulator profile - showing broad-spectrum efficacy including negative symptoms, which most current antipsychotics fail to treat.
• Xanomeline-trospium (KarXT/Cobenfy): FDA approved September 2024 - the first truly novel mechanism antipsychotic in 30 years. It acts on muscarinic M1/M4 receptors rather than dopamine D2 receptors. It avoids dopamine-related side effects (EPS, tardive dyskinesia, hyperprolactinemia) while showing antipsychotic efficacy across positive, negative, and cognitive symptoms. This is regarded as the biggest mechanistic shift in antipsychotic therapy since the introduction of clozapine.
• Risperidone ER (Uzedy): Subcutaneous long-acting injectable risperidone, FDA approved 2023, now also approved for Bipolar I disorder (October 2025) - providing an injectable option for mood stabilization.

17. Transcranial Direct Current Stimulation (tDCS) - First At-Home Device

• Flow tDCS device: FDA cleared December 2025 as the first at-home transcranial direct current stimulation device for depression. Patients apply mild electrical current (1-2 mA) to the prefrontal cortex via a headset, without visiting a clinic.
• This represents a major shift in how neuromodulation can be delivered - scalable, self-administered, and affordable compared to clinic-based TMS.
• tDCS has a large supporting evidence base from Europe (widely used in the UK and Scandinavia) and the device's FDA clearance will substantially accelerate US adoption.

18. The Gut-Brain Axis and Psychobiotics

• Psychobiotics (probiotics/prebiotics with mental health effects) have moved from theoretical to clinical investigation. Multiple 2024 reviews (PMIDs: 38613087, 38914414) confirm that specific Lactobacillus and Bifidobacterium strains reduce depression and anxiety scores in RCTs, though effect sizes remain moderate.
• Fecal microbiota transplant (FMT) has been explored in clinical trials for depression and autism spectrum disorder.
• The microbiota-gut-brain axis is now an established research area with a dedicated journal (Gut Microbiome). Key mechanistic pathways: vagal nerve signaling, short-chain fatty acid production, tryptophan/serotonin metabolism, and HPA axis modulation.
• A 2025 review (PMID: 39713871) mapped the current evidence base and ongoing clinical trials.

19. Long-Acting Injectables (LAIs) - Growing Evidence for Early Use

• Historically, LAIs (depot antipsychotics) were seen as a last resort for non-adherent patients. The evidence base now supports their use early in illness.
• A 2025 umbrella review (PMID: 40068445) found LAIs in early psychosis significantly reduce relapse rates, hospitalizations, and all-cause mortality compared to oral antipsychotics.
• New LAI formulations have extended dosing intervals: Paliperidone 6-month injectable (Invega Hafyera) approved 2021 - just 2 injections per year, the longest dosing interval for any antipsychotic.

20. Key 2025 Clinical Guideline Changes

21. Navacaprant - Kappa-Opioid Receptor Antagonist for Depression

• Navacaprant is in Phase III trials (results 2023-2024) as a kappa-opioid receptor antagonist for depression - a completely different mechanism from all current antidepressants.
• Kappa-opioid receptors mediate dysphoria and anhedonia. Blocking them reduces emotional blunting and anhedonia that SSRIs often fail to address.
• If approved, it would be the first kappa-opioid antagonist approved for a psychiatric indication.

22. Updated Understanding of Suicide Prevention

• Stanley-Brown Safety Planning Intervention (SPI) and the Zero Suicide framework are now widely adopted in healthcare systems and have been validated in large studies as reducing suicidal crises.
• Lithium's antisuicidal effect has been further confirmed: it is the only psychotropic drug with robust meta-analytic evidence for reducing suicide and suicide attempts, independent of mood stabilization.
• Esketamine/ketamine approval for acute suicidal ideation (2020) gave emergency psychiatry its first rapidly acting pharmacological tool for acute suicidal crises.
• Means restriction counseling (specifically firearm storage counseling) is now formally incorporated into psychiatric safety planning guidelines.

Summary of What's New Since the First Response